Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.54 USD | +0.16% | +7.09% | -17.23% |
Financials (USD)
Sales 2024 * | 29.08M | Sales 2025 * | 2.68M | Capitalization | 891M |
---|---|---|---|---|---|
Net income 2024 * | -199M | Net income 2025 * | -297M | EV / Sales 2024 * | 12.5 x |
Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 200 x |
P/E ratio 2024 * |
-4.46
x | P/E ratio 2025 * |
-3.39
x | Employees | 124 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.73% |
Latest transcript on Zentalis Pharmaceuticals, Inc.
1 day | +0.16% | ||
1 week | +7.09% | ||
Current month | +13.38% | ||
1 month | -14.87% | ||
3 months | +9.04% | ||
6 months | +27.44% | ||
Current year | -17.23% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.07% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 12.54 | +0.16% | 620,927 |
24-05-09 | 12.52 | +0.72% | 592,439 |
24-05-08 | 12.43 | +0.97% | 1,022,881 |
24-05-07 | 12.31 | +5.03% | 518,363 |
24-05-06 | 11.72 | +0.09% | 284,358 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.23% | 891M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ZNTL Stock